| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| BiomX Inc. | 10%+ Owner | Common Stock, par value $0.0001 per share | 1,787,758 | $1,663,688 | $0.9306 | 15 Jul 2024 | Direct |
| BiomX Inc. | 10%+ Owner | Common Stock, par value $0.0001 per share | 9,330,580 | 15 May 2024 | Direct | ||
| Aridis Pharmaceuticals, Inc. | 10%+ Owner | Common Stock, par value $0.0001 per share | 5,168,732 | 08 Dec 2022 | Direct | ||
| BiomX Inc. | 10%+ Owner | Series X Preferred Stock | 13,088 | 15 Jul 2024 | Direct | ||
| BiomX Inc. | 10%+ Owner | Warrant to purchase common stock | 0 | 15 May 2024 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| PHGE | BiomX Inc. | 26 Feb 2025 | 0 | $0 | 4 | 10%+ Owner | 04 Mar 2025, 16:36 |
| PHGE | BiomX Inc. | 15 Jul 2024 | 2 | $0 | 5 | 10%+ Owner | 04 Mar 2025, 16:31 |
| PHGE | BiomX Inc. | 15 May 2024 | 2 | +$4,778 | 4 | 10%+ Owner | 17 May 2024, 16:05 |
| PHGE | BiomX Inc. | 16 Mar 2024 | 0 | $0 | 3 | 10%+ Owner | 26 Mar 2024, 16:30 |
| /report/000089924322038926-cystic-fibrosis-foundation-2022-12-08 | Aridis Pharmaceuticals, Inc. | 08 Dec 2022 | 0 | $0 | 3 | 10%+ Owner | 19 Dec 2022, 05:05 |